

**Table S1.** Characteristics of the selected protocols registered on the clinicaltrials.gov database.

NCT Code	Intervention (s)	Phase	Enrollment
NCT01224106	Drug: Gantenerumab Drug: Placebo	Phase 3	799
NCT01300728	Drug: NewGam 10% IVIG Other: Placebo	Phase 2	52
NCT01703117	Drug: Riluzole Drug: Placebo	Phase 2	42
NCT01760005	Drug: Gantenerumab Drug: Solanezumab Drug: Matching Placebo (Gantenerumab) Drug: Matching Placebo (Solanezumab)	Phase 2 Phase 3	490
NCT01767311	Drug: BAN2401 2.5 mg/kg Drug: BAN2401 5.0 mg/kg Drug: BAN2401 10 mg/kg Drug: Placebo	Phase 2	856
NCT01811381	Drug: Curcumin Behavioral: Aerobic yoga Behavioral: Non aerobic yoga Dietary Supplement: Placebo	Phase 2	80
NCT01843075	Drug: Liraglutide Drug: Placebo	Phase 2	204
NCT01998841	Drug: Crenezumab Drug: Placebo	Phase 2	252
NCT02008357	Drug: Placebo Drug: Solanezumab	Phase 3	1150
NCT02033941	Drug: Meganatural-Az Grapeseed Extract Drug: Placebo	Phase 2	20
NCT02051608	Drug: Gantenerumab Drug: Placebo	Phase 3	389
NCT02054208	Biological: Human umbilical cord blood derived mesenchymal stem cells Other: Normal saline 2 mL	Phase 1 Phase 2	45
NCT02085265	Drug: Perindopril Drug: Telmisartan	Phase 2	150
NCT02292238	Drug: Benfotiamine	Phase 2	76
NCT02547818	Drug: ALZT-OP1a Drug: ALZT-OP1b Other: Placebo ALZT-OP1a Other: Placebo ALZT-OP1b	Phase 3	620
NCT02600130	Biological: Longeveron Mesenchymal Stem Cells Biological: Placebo	Phase 1	33
NCT02646982	Drug: Placebo Drug: Candesartan	Phase 2	72
NCT02726906	Behavioral: Moderate-aerobic walking Radiation: Positron Emission Tomography (PET) scan Behavioral: Healthy living education Device: Physical activity monitor	Phase 2	100
NCT02833792	Drug: Human Mesenchymal Stem Cells and Lactated Riunger's Solution Other: Placebo	Phase 2	40
NCT02880956	Drug: ABBV-8E12 Drug: Placebo for ABBV-8E12	Phase 2	453
NCT02899091	Biological: CB-AC-02 Biological: Placebo	Phase 1 Phase 2	24
NCT02913664	Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) Behavioral: Aerobic Exercise Training Other: Usual Care Behavioral: Stretching Exercise Drug: Atorvastatin	Phase 2 Phase 3	513
NCT02925650	Drug: Posiphen Drug: Placebo	Phase 1 Phase 2	24
NCT02931136	Drug: Huperzine A Drug: Placebo	Phase 4	300
NCT02947893	Drug: Placebo Capsule(s) Once a Day by Mouth Drug: Nilotinib Capsule(s) Once a Day by Mouth	Phase 2	42
NCT02956486	Drug: Elenbecestat (E2609) Drug: Placebo	Phase 3	1181
NCT03036280	Drug: Elenbecestat (E2609) Drug: Placebo	Phase 3	1018
NCT03061474	Drug: Nicotinamide Drug: Placebo Comparator	Phase 2	48
NCT03069014	Drug: 400 mg LM11A-31-BHS Drug: 800 mg LM11A-31-BHS Drug: Placebos	Phase 1 Phase 2	242
NCT03090516	Drug: Ginkgo biloba dispersible tablets Drug: Donepezil Drug: Ginkgo biloba dispersible tablets and Donepezil	Phase 2 Phase 3	240
NCT03094546	Dietary Supplement: Polyamine Dietary Supplement: Placebo	Phase 2	100
NCT03131453	Drug: CNP520 50 mg Drug: CNP520 15 mg Other: Placebo to CNP520	Phase 2 Phase 3	1147
NCT03172117	Biological: human umbilical cord blood derived mesenchymal stem cells Other: Normal saline 2 mL	Phase 1 Phase 2	45
NCT03185208	Drug: Lithium Carbonate Drug: Placebo oral capsule	Phase 4	80
NCT03186989	Drug: IONIS MAPTRx Other: Placebo	Phase 1 Phase 2	46
NCT03234686	Drug: Deferiprone 600 mg delayed release tablets Drug: Placebo Oral Tablet	Phase 2	171
NCT03274817	Drug: Escitalopram Pill Drug: Venlafaxine Pill Drug: Placebo Oral Tablet	Phase 1	31
NCT03277573	Drug: Salsalate Drug: Placebo	Phase 1	40
NCT03282916	Drug: Valacyclovir Drug: Placebo	Phase 2	130
NCT03289143	Drug: Semorinemab Drug: Placebo Drug: [18F] GTP1	Phase 2	457
NCT03361410	Dietary Supplement: Grape Powder Dietary Supplement: Placebo Powder	Phase 2	32
NCT03367403	Drug: LY3002813 Drug: Placebo	Phase 2	266
NCT03417986	Drug: TEP	Phase 2	100
NCT03435861	Drug: VX-745 Drug: Placebo	Phase 2	40
NCT03441516	Drug: Alfoatirin- $\alpha$ E Table + Aripezil- $\alpha$ E Tab. Drug: Aripezil- $\alpha$ E Tab.	Phase 4	79
NCT03443973	Drug: Gantenerumab Drug: Placebo	Phase 3	1016
NCT03444870	Drug: Gantenerumab Drug: Placebo	Phase 3	1016
NCT03446001	Drug: TRx0237 16 mg/day Drug: Placebo Drug: TRx0237 8 mg/day	Phase 3	450
NCT03461276	Biological: ABvac40 Biological: Placebo	Phase 2	120
NCT03486938	Drug: Placebo Oral Tablet Drug: AGB101 220 mg tablet	Phase 3	830
NCT03493282	Drug: Active Treatment- CT1812 100 mg Drug: Placebo Drug: Active Treatment- CT1812 300 mg	Phase 1 Phase 2	23
NCT03507790	Drug: CT1812 Drug: Placebo	Phase 2	120
NCT03518073	Drug: LY3303560 Drug: Placebo	Phase 2	285
NCT03522129	Drug: CT1812 Drug: Placebo	Phase 1	18
NCT03533257	Drug: AMX0035 Drug: Placebo	Phase 2	100

NCT03634007	Biological: AAVrh.10hPOE2 vector	Phase 1	15
NCT03649724	Drug: Placebo Drug: Eligard 22.5 Mg Suspension for Injection	Phase 2	180
NCT03712787	Drug: ABBV-8E12	Phase 2	360
NCT03748303	Drug: Allopregnanolone	Phase 1	12
NCT03752294	Drug: Dabigatran Drug: Placebo—Cap	Phase 1	40
NCT03790709	Drug: High dose ANAVEX2-73 Drug: Mid dose ANAVEX2-73 Drug: Placebo oral capsule	Phase 2 Phase 3	450
NCT03790982	Drug: Placebo of AD-35 60 mg/AD-35 30 mg Drug: Placebo of AD-35 60 mg/AD-35 60 mg Drug: AD-35 30 mg + Placebo of AD-35 30 mg Drug: AD-35 60 mg	Phase 2	240
NCT03801642	Drug: Dapagliflozin Other: Placebo	Phase 1 Phase 2	48
NCT03823404	Drug: COR388 capsule Drug: Placebo capsule	Phase 2 Phase 3	573
NCT03828747	Drug: Semorinemab Drug: Placebo Drug: [18F] GTP1	Phase 2	260
NCT03865017	Biological: Regulatory T cells Other: Saline	Phase 1 Phase 2	20
NCT03867253	Drug: ORY-2001 Low dose Drug: ORY-2001 High dose Drug: Placebo	Phase 2	33
NCT03875638	Drug: Levetiracetam Drug: Placebo oral capsule	Phase 2	85
NCT03880240	Device: Transcranial Alternating Current Stimulation (tACS) Other: Sham Transcranial Alternating Current Stimulation	Phase 1 Phase 2	55
NCT03887455	Drug: BAN2401 Drug: Placebo	Phase 3	1566
NCT03919162	Drug: PQ912 Other: Placebo	Phase 2	462
NCT03943264	Drug: XPro1595	Phase 1	18
NCT03977584	Drug: Crenezumab Drug: Placebo Other: [18F] GTP1	Phase 2	150
NCT03980730	Drug: Azeliragon Drug: Placebo	Phase 2 Phase 3	300
NCT03991988	Drug: Montelukast Drug: Placebo oral tablet	Phase 2	150
NCT04032626	Drug: Lenalidomide 10 mg Drug: Placebos	Phase 2	30
NCT04044131	Drug: Metabolic Cofactor Supplementation Drug: Sorbitol	Phase 2	120
NCT04052737	Drug: Normal Saline along with standard treatment Drug: PMZ-1620 (sovateotide) along with standard treatment	Phase 2	80
NCT04070378	Drug: Daratumumab Injection	Phase 2	15
NCT04079803	Drug: Placebo oral tablet Drug: PTI-125 50 mg tablet Drug: PTI-125 100 mg oral tablet	Phase 2	60
NCT04149860	Drug: Lu AF87908 Drug: Placebo	Phase 1	96
NCT04187547	Drug: Tricaprilin Drug: Placebo	Phase 3	300
NCT04191486	Drug: T-817MA Drug: Placebo	Phase 2	200
NCT04205539	Drug: Dexmedetomidine	Phase 1	50
NCT04228666	Drug: HB-adMSCs	Phase 1 Phase 2	24
NCT04241068	Drug: Aducanumab	Phase 3	2400
NCT04263519	Drug: Tacrolimus	Phase 2	12
NCT04311515	Radiation: Tau Positron emission tomography (PET) Radiation: Fluorodeoxyglucose (FDG) Positron emission tomography (PET) Diagnostic Test: Cerebrospinal fluid (CSF) Biomarkers Diagnostic Test: Blood Biomarkers Behavioral: Rating Scales Drug: PU-AD Drug: Placebo	Phase 2	150
NCT04314934	Drug: ANAVEX2-73	Phase 2 Phase 3	450
NCT04339413	Drug: Gantenerumab	Phase 3	173
NCT04374253	Drug: Gantenerumab	Phase 3	2032
NCT04381468	Drug: Pepinemab Drug: Placebo	Phase 1 Phase 2	60